MiRs-17-92 undergo increased expression in primary CD34+ CML cells in the chronic phase but not during blast crisis, raising a potential collaboration between BCR-ABL c-MYC-miR-17-92.   39. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.